News

Proteome Sciences announces its unaudited interim results for the six months ended 30 June 2023.

The Directors of Proteome are pleased to announce that the Company has today repaid in full the outstanding loan and associated interest (together totalling £824,424) to Vulpes Investment Management Private Limited originally announced on 2 July 2018 and amended on 30 March 2022.

The directors of Proteome Sciences are pleased to announce that at the Company's AGM, held at 12.00 p.m. today, all resolutions were duly passed.

Annual General Meeting (AGM) Statement

Proteome Sciences plc is pleased to announce the expansion of its proteomics services into the United States of America (“US”). 

The Company has received notification from Vulpes Investment Management Pte Ltd ("Vulpes") that on 12 and 13 April 2023 it purchased, respectively, 100,000 and 100,000 ordinary shares of 1p in the capital of the Company ("Ordinary Shares") at a price of 4p per Ordinary Share (the “Purchase”). Following the Purchase, Vulpes has a total direct and indirect interest in 67,789,772 Ordinary Shares, equivalent to 22.97% of Proteome Sciences' total issued share capital.

The Company has received notification from Vulpes Investment Management Pte Ltd ("Vulpes") that on 4 and 5 April 2023 it purchased, respectively, 14,766 and 100,000 ordinary shares of 1p in the capital of the Company ("Ordinary Shares") at a price of 4p per Ordinary Share (the “Purchase”). Following the Purchase, Vulpes has a total direct and indirect interest in 67,589,772 Ordinary Shares, equivalent to 22.89% of Proteome Sciences' total issued share capital.

Proteome Sciences plc is pleased to announce that Chief Executive Officer, Dr Mariola Soehngen, will provide a live presentation relating to the Year End Results via the Investor Meet Company platform on 19 April 2023 at 10:00am BST.

The Company is pleased to announce its audited results for the year ended 31 December 2022.